"Antiangiogenn\u00ED l\u00E9\u010Dba metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu - anal\u00FDza dat z dvou center"@cs . . "RIV/00216224:14110/10:00051803!RIV12-MSM-14110___" . . "Onkologie" . . "RIV/00216224:14110/10:00051803" . "The primary endpoint of this retrospective analysis was PFS, OS and RR in the group of the patients treated with the first line chemotherapy and bevacizumab. As secondary endopoint we also analysed a treatment toxicity and selected prognostic a and predictive factors. Patients and methods: We analysed data from AVASTIN register completed with a clinical and laboratory informations. In relation with results we analysed: age, number of metastatic sites, KRAS status and hypertension. Results: Two hundert two pts were treated with chemotherapy and bevacizumab. The median follow up was 9,7months. The median progression-free was 11,3 months, median overall survival 30,6 months. Arterial hypertension didnt correlate with the clinical outcome. The main adverse events were hypertension and thromboembolic events. Conclusions: Bevacizumab is a common part of the first line treatment of patients with mCRC in the Czech Republic."@en . . "4" . "I, V" . "bevacizumab; colorectal cancer; treatment"@en . . . "Vyzula, Rostislav" . "3" . "8"^^ . "Navr\u00E1til, J." . "Abrah\u00E1mov\u00E1, J." . "C\u00EDlem retrospektivn\u00ED studie bylo zhodnocen\u00ED p\u0159e\u017Eit\u00ED bez progrese onemocn\u011Bn\u00ED (PFS), d\u00E1le celkov\u00E9ho p\u0159e\u017Eit\u00ED (OS) a odpov\u011Bdi (RR) v souboru pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem (mCRC) l\u00E9\u010Den\u00FDch prvn\u00ED lini\u00ED paliativn\u00ED chemoterapie v kombinaci s bevacizumabem. Sekund\u00E1rn\u00EDm c\u00EDlem byla anal\u00FDza toxicity terapie a vyhodnocen\u00ED vybran\u00FDch prognostick\u00FDch a prediktivn\u00EDch faktor\u016F. Pacienti a metody: V anal\u00FDze byly vyu\u017Eity n\u011Bkter\u00E9 \u00FAdaje z registru AVASTIN dopln\u011Bn\u00E9 o dal\u0161\u00ED klinick\u00E9 a laboratorn\u00ED parametry. Ve vztahu k v\u00FDsledku terapie jsme analyzovali i n\u00E1sleduj\u00EDc\u00ED prom\u011Bnn\u00E9: v\u011Bk, po\u010Det metastatick\u00FDch lokalizac\u00ED, p\u0159\u00EDtomnost mutace KRAS, p\u0159\u00EDtomnost hypertenze jako komorbidity p\u0159i zah\u00E1jen\u00ED l\u00E9\u010Dby a hypertenzn\u00ED reakci na l\u00E9\u010Dbu bevacizumabem. V\u00FDsledky: 202 pacient\u016F s medi\u00E1nem sledov\u00E1n\u00ED 9,7M bylo l\u00E9\u010Deno bevacizumabem (152 pacient\u016F MO\u00DA a 50 pacient\u016F FTN). Medi\u00E1n p\u0159e\u017Eit\u00ED bez zn\u00E1mek progrese (PFS) byl 11,3 m\u011Bs\u00EDc\u016F, medi\u00E1n celkov\u00E9ho p\u0159e\u017Eit\u00ED (OS) 30,6 m\u011Bs\u00EDc\u016F." . "\u0160t\u00EDcha, M." . . "247065" . . "B\u00FCchler, T." . "14110" . "Ka\u0148\u00E1kov\u00E1, J." . "CZ - \u010Cesk\u00E1 republika" . "[533A88318ED9]" . "C\u00EDlem retrospektivn\u00ED studie bylo zhodnocen\u00ED p\u0159e\u017Eit\u00ED bez progrese onemocn\u011Bn\u00ED (PFS), d\u00E1le celkov\u00E9ho p\u0159e\u017Eit\u00ED (OS) a odpov\u011Bdi (RR) v souboru pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem (mCRC) l\u00E9\u010Den\u00FDch prvn\u00ED lini\u00ED paliativn\u00ED chemoterapie v kombinaci s bevacizumabem. Sekund\u00E1rn\u00EDm c\u00EDlem byla anal\u00FDza toxicity terapie a vyhodnocen\u00ED vybran\u00FDch prognostick\u00FDch a prediktivn\u00EDch faktor\u016F. Pacienti a metody: V anal\u00FDze byly vyu\u017Eity n\u011Bkter\u00E9 \u00FAdaje z registru AVASTIN dopln\u011Bn\u00E9 o dal\u0161\u00ED klinick\u00E9 a laboratorn\u00ED parametry. Ve vztahu k v\u00FDsledku terapie jsme analyzovali i n\u00E1sleduj\u00EDc\u00ED prom\u011Bnn\u00E9: v\u011Bk, po\u010Det metastatick\u00FDch lokalizac\u00ED, p\u0159\u00EDtomnost mutace KRAS, p\u0159\u00EDtomnost hypertenze jako komorbidity p\u0159i zah\u00E1jen\u00ED l\u00E9\u010Dby a hypertenzn\u00ED reakci na l\u00E9\u010Dbu bevacizumabem. V\u00FDsledky: 202 pacient\u016F s medi\u00E1nem sledov\u00E1n\u00ED 9,7M bylo l\u00E9\u010Deno bevacizumabem (152 pacient\u016F MO\u00DA a 50 pacient\u016F FTN). Medi\u00E1n p\u0159e\u017Eit\u00ED bez zn\u00E1mek progrese (PFS) byl 11,3 m\u011Bs\u00EDc\u016F, medi\u00E1n celkov\u00E9ho p\u0159e\u017Eit\u00ED (OS) 30,6 m\u011Bs\u00EDc\u016F."@cs . . . "2"^^ . . . "Obermannov\u00E1, Radka" . . "Slamov\u00E1, L." . "Antiangiogenn\u00ED l\u00E9\u010Dba metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu - anal\u00FDza dat z dvou center" . . "1802-4475" . . "Antiangiogenn\u00ED l\u00E9\u010Dba metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu - anal\u00FDza dat z dvou center"@cs . "Antiangiogenn\u00ED l\u00E9\u010Dba metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu - anal\u00FDza dat z dvou center" . "4"^^ . "Anti-angiogenic therapy for metastatic colorectal cancer \u2013 analysis of date from two centers"@en . . "Anti-angiogenic therapy for metastatic colorectal cancer \u2013 analysis of date from two centers"@en .